Literature DB >> 28792701

Predictive Value of Hepatitis B Core-Related Antigen (HBcrAg) During the Natural History of Hepatitis B Virus Infection.

Yu Gou, Yanhua Zhao, Chenli Rao, Shu Feng, Tingting Wang, Dongdong Li, Chuanmin Tao.   

Abstract

BACKGROUND: The natural history of HBV infection includes immune tolerance (IT), immune clearance (IC), HBeAg-negative inactive/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH) phases. As the current biomarkers for discriminating the four phases still have some weaknesses, additional serological indicators are needed. Hepatitis B core-related antigen (HBcrAg) encoded with the precore/core gene contains denatured HBeAg, HBV core antigen (HBcAg), and a 22-KDa precore protein (p22cr) and has been demonstrated to have a close association with the natural history of hepatitis B infection. However, no specific cutoff values and diagnostic parameters have been identified to evaluate the diagnostic efficacy. This study aimed to clarify the distribution of HBcrAg levels and evaluate the diagnostic performance during the natural history of HBV infection in a Western Chinese population.
METHODS: In this study, 294 samples were collected from treatment-naive HBV infection patients in different phases (IT = 64; IC = 72; ENQ = 100, and ENH = 58). We detected the HBcrAg values and analyzed the relationship between HBcrAg and HBV DNA. HBsAg and other clinical parameters were quantitatively detected.
RESULTS: The HBcrAg levels of IT, IC, ENQ, and ENH were 9.30 log U/mL, 8.80 log U/mL, 3.00 log U/mL, and 5.10 log U/mL, respectively (p < 0.0001). Receiver operating characteristic curve analysis demonstrated that the areas under the curves (AUCs) for HBcrAg and quantitative HBsAg at cutoff values of 9.25 log U/mL and 4.355 log IU/mL for distinguishing the IT phase from the IC phase were 0.704 and 0.694, with a sensitivity of 53.13% and 79.69% and specificity of 76.39% and 59.72%, respectively. AUCs of HBcrAg and quantitative HBsAg at cutoff values of 4.15 log U/mL and 2.395 log IU/mL for discriminating between the ENQ and ENH phases were 0.931 and 0.653, with a sensitivity of 87.93% and 91.38% and specificity of 84.00% and 39.00%, respectively.
CONCLUSIONS: HBcrAg levels varied significantly among the four natural phases of HBV infection and had higher predictive performance than quantitative HBsAg for distinguishing between ENQ-patients and ENH-patients and a similar performance as HBsAg for the discrimination between IT and IC phases, which indicated that HBcrAg could be a potential serological marker for HBV infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28792701     DOI: 10.7754/Clin.Lab.2017.161034

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  4 in total

1.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

2.  Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis.

Authors:  Zhan Qing Zhang; Yan Bing Wang; Wei Lu; Dan Ping Liu; Bi Sheng Shi; Xiao Nan Zhang; Dan Huang; Xiu Fen Li; Xin Lan Zhou; Rong Rong Ding
Journal:  Ann Lab Med       Date:  2019-01       Impact factor: 3.464

3.  Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B.

Authors:  Guichan Liao; Xia Ding; Muye Xia; Yin Wu; Hongjie Chen; Rong Fan; Xiaoyong Zhang; Shaohang Cai; Jie Peng
Journal:  Int J Gen Med       Date:  2021-08-28

4.  Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.

Authors:  Marc G Ghany; Wendy C King; Mauricio Lisker-Melman; Anna S F Lok; Norah Terrault; Harry L A Janssen; Mandana Khalili; Raymond T Chung; William M Lee; Daryl T Y Lau; Gavin A Cloherty; Richard K Sterling
Journal:  Hepatology       Date:  2021-09-09       Impact factor: 17.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.